Brokerages Set Neos Therapeutics Inc (NASDAQ:NEOS) Price Target at $7.25

Shares of Neos Therapeutics Inc (NASDAQ:NEOS) have earned an average rating of “Buy” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $7.25.

A number of equities research analysts have weighed in on NEOS shares. ValuEngine raised shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 10th. BMO Capital Markets cut their price target on shares of Neos Therapeutics from $4.00 to $3.00 and set a “market perform” rating for the company in a report on Monday, August 12th. Finally, Cantor Fitzgerald cut their price target on shares of Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, June 12th.

NEOS stock traded down $0.04 during trading on Tuesday, hitting $1.39. The company had a trading volume of 400 shares, compared to its average volume of 186,121. The firm has a market capitalization of $70.12 million, a price-to-earnings ratio of -0.87 and a beta of 0.92. The business has a 50 day moving average of $1.78 and a 200 day moving average of $1.81. Neos Therapeutics has a fifty-two week low of $1.13 and a fifty-two week high of $4.78. The company has a current ratio of 1.13, a quick ratio of 0.91 and a debt-to-equity ratio of 41.70.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.09. The company had revenue of $15.64 million during the quarter, compared to analyst estimates of $16.70 million. As a group, equities analysts predict that Neos Therapeutics will post -0.5 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Arbitrage SA lifted its holdings in Neos Therapeutics by 1,749.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 10,098 shares of the company’s stock valued at $26,000 after acquiring an additional 9,552 shares during the last quarter. Weiss Asset Management LP acquired a new stake in Neos Therapeutics in the 2nd quarter valued at about $36,000. Acadian Asset Management LLC acquired a new stake in Neos Therapeutics during the 2nd quarter worth about $40,000. D. E. Shaw & Co. Inc. acquired a new stake in Neos Therapeutics during the 2nd quarter worth about $57,000. Finally, Rhumbline Advisers raised its holdings in Neos Therapeutics by 43.5% during the 1st quarter. Rhumbline Advisers now owns 53,730 shares of the company’s stock worth $140,000 after buying an additional 16,288 shares during the period. 45.86% of the stock is owned by institutional investors.

About Neos Therapeutics

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Read More: How can you know how many shares are floating?

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.